- Home
- MAC vs SRRK Comparison
MAC vs SRRK Comparison
Compare MAC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | SRRK |
|---|---|---|
| Founded | 1964 | 2012 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MAC | SRRK |
|---|---|---|
| Price | $21.60 | $49.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $20.50 | ★ $55.64 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 11.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.70 | $544.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $13.86 | $27.07 |
| 52 Week High | $21.40 | $51.63 |
Technical Indicators
Market Signals| Indicator | MAC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 72.18 | 59.51 |
| Support Level | $17.84 | $42.52 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.53 | 2.10 |
| MACD | 0.31 | 0.41 |
| Stochastic Oscillator | 92.98 | 79.15 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.